Chenglong Han

7PUBLICATIONS
26CO-AUTHORS
Clinical neuropsychologySystems physiologyHealth psychologyGeriatrics and gerontologyShip and platform structures (incl. maritime hydrodynamics)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (7)

|Feb 22, 2024
Work Productivity and General Health Through 2 Years of Guselkumab Treatment in a Phase 3 Randomized Trial of Patients With Active Psoriatic Arthritis.

Jeffrey R Curtis, Iain B McInnes, Proton Rahman

|Nov 14, 2023
Qualitative and psychometric evaluation of the PROMIS®-Fatigue SF-7a scale to assess fatigue in patients with moderately to severely active inflammatory bowel disease.

Brian G Feagan, William J Sandborn, Bruce E Sands

|Jul 15, 2021
Guselkumab demonstrated an independent treatment effect in reducing fatigue after adjustment for clinical response-results from two phase 3 clinical trials of 1120 patients with active psoriatic arthritis.

Proton Rahman, Philip J Mease, Philip S Helliwell

|Sep 10, 2020
Maintenance of Response Through up to 4 Years of Continuous Guselkumab Treatment of Psoriasis in the VOYAGE 2 Phase 3 Study.

Kristian Reich, April W Armstrong, Peter Foley

|Jul 15, 2020
Continuous treatment with guselkumab maintains clinical responses through 4 years in patients with moderate-to-severe psoriasis: results from VOYAGE 1.

Christopher E M Griffiths, Kim A Papp, Michael Song

|Jul 16, 2019
Guselkumab improves work productivity in patients with moderate-to-severe psoriasis with or without depression and anxiety: results from the VOYAGE 2 comparator study versus adalimumab.

Kristian Reich, Peter Foley, Chenglong Han

Pageof 2

Frequent Collaborators

2 joint publications

Kristian Reich

2 joint publications

Peter Foley

2 joint publications

April W Armstrong

1 joint publications

Laura K Ferris